Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154864146> ?p ?o ?g. }
- W2154864146 endingPage "232" @default.
- W2154864146 startingPage "227" @default.
- W2154864146 abstract "The purpose of this study was to evaluate the impact of a dose-dense primary chemotherapy on pathological response rate (pCR) in patients with locally advanced breast cancer (LABC) treated with combined modality therapy.Stage IIIA/IIIB patients received three courses of induction chemotherapy (ICT) with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by local therapy (total mastectomy or segmental mastectomy with axillary nodes dissection) and adjuvant chemotherapy (ACT) with three courses of CEF alternated with three courses of cyclophosphamide, methotrexate, 5-fluorouracil (CMF). Patients were randomized to receive ICT and ACT every 3 weeks (arm A, 'standard treatment') or every 2 weeks with granulocyte-macrophage colony-stimulating factor (GM-CSF) support (arm B, 'dose-dense treatment'). In both arms radiotherapy was administered after the end of chemotherapy (in selected cases) and patients with hormonal receptor-positive tumors received tamoxifen for 5 years.A total of 150 patients were randomized (77 arm A and 73 arm B) and demographics were well balanced between the two arms. Compliance to treatment was excellent: 95% and 93% of patients in arms A and B, respectively, completed the treatment program with no modification or delay. Median duration of treatment (ICT+local+ACT) was 183 days (range 0-265) in arm A and 139 days (0-226) in arm B. The average relative dose intensity (ARDI) of chemotherapy was 1.3 with a 30% increase in the dose intensity in arm B in comparison with arm A. No difference in clinical [62%; 95% confidence interval (CI) 49% to 73.2%] and pathological response rates to ICT was observed between the two arms. Median follow-up was 5 years (range 1-96 months); median disease-free survivals were 4.8 years in arm A and 4.5 years in arm B. Median overall survival was 7.8 years in standard therapy: this figure has not yet been reached in the dose-dense treatment.In LABC a dose-dense regimen, while allowing a 30% increase in the dose intensity of chemotherapy, did not provide significant improvement in pathological response rates. However, accelerated chemotherapy reduced the duration of the combined-modality program (6.1 versus 4.6 months) with no additional toxicities." @default.
- W2154864146 created "2016-06-24" @default.
- W2154864146 creator A5002470794 @default.
- W2154864146 creator A5016015594 @default.
- W2154864146 creator A5019031494 @default.
- W2154864146 creator A5026665975 @default.
- W2154864146 creator A5030106365 @default.
- W2154864146 creator A5034987953 @default.
- W2154864146 creator A5047821555 @default.
- W2154864146 creator A5052751530 @default.
- W2154864146 creator A5060387971 @default.
- W2154864146 creator A5062442517 @default.
- W2154864146 creator A5076610275 @default.
- W2154864146 creator A5089283304 @default.
- W2154864146 date "2003-02-01" @default.
- W2154864146 modified "2023-10-15" @default.
- W2154864146 title "Accelerated versus standard cyclophosphamide, epirubicin and5-fluorouracil or cyclophosphamide, methotrexate and5-fluorouracil: a randomized phase III trial in locally advanced breast cancer" @default.
- W2154864146 cites W1544231811 @default.
- W2154864146 cites W1898988182 @default.
- W2154864146 cites W1900639705 @default.
- W2154864146 cites W1915574909 @default.
- W2154864146 cites W2008686530 @default.
- W2154864146 cites W2017531518 @default.
- W2154864146 cites W2018669222 @default.
- W2154864146 cites W2023141201 @default.
- W2154864146 cites W2034991781 @default.
- W2154864146 cites W2095259252 @default.
- W2154864146 cites W2133764807 @default.
- W2154864146 cites W2139510434 @default.
- W2154864146 cites W2142446557 @default.
- W2154864146 cites W2161897297 @default.
- W2154864146 cites W2174514097 @default.
- W2154864146 cites W2185154108 @default.
- W2154864146 cites W2222885112 @default.
- W2154864146 cites W2270235662 @default.
- W2154864146 cites W2340435826 @default.
- W2154864146 cites W2396326323 @default.
- W2154864146 cites W4237434210 @default.
- W2154864146 cites W4293241248 @default.
- W2154864146 cites W4362046093 @default.
- W2154864146 doi "https://doi.org/10.1093/annonc/mdg069" @default.
- W2154864146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12562649" @default.
- W2154864146 hasPublicationYear "2003" @default.
- W2154864146 type Work @default.
- W2154864146 sameAs 2154864146 @default.
- W2154864146 citedByCount "60" @default.
- W2154864146 countsByYear W21548641462012 @default.
- W2154864146 countsByYear W21548641462013 @default.
- W2154864146 countsByYear W21548641462014 @default.
- W2154864146 countsByYear W21548641462015 @default.
- W2154864146 countsByYear W21548641462016 @default.
- W2154864146 countsByYear W21548641462017 @default.
- W2154864146 countsByYear W21548641462018 @default.
- W2154864146 countsByYear W21548641462019 @default.
- W2154864146 countsByYear W21548641462020 @default.
- W2154864146 countsByYear W21548641462021 @default.
- W2154864146 countsByYear W21548641462023 @default.
- W2154864146 crossrefType "journal-article" @default.
- W2154864146 hasAuthorship W2154864146A5002470794 @default.
- W2154864146 hasAuthorship W2154864146A5016015594 @default.
- W2154864146 hasAuthorship W2154864146A5019031494 @default.
- W2154864146 hasAuthorship W2154864146A5026665975 @default.
- W2154864146 hasAuthorship W2154864146A5030106365 @default.
- W2154864146 hasAuthorship W2154864146A5034987953 @default.
- W2154864146 hasAuthorship W2154864146A5047821555 @default.
- W2154864146 hasAuthorship W2154864146A5052751530 @default.
- W2154864146 hasAuthorship W2154864146A5060387971 @default.
- W2154864146 hasAuthorship W2154864146A5062442517 @default.
- W2154864146 hasAuthorship W2154864146A5076610275 @default.
- W2154864146 hasAuthorship W2154864146A5089283304 @default.
- W2154864146 hasBestOaLocation W21548641461 @default.
- W2154864146 hasConcept C121608353 @default.
- W2154864146 hasConcept C126322002 @default.
- W2154864146 hasConcept C141071460 @default.
- W2154864146 hasConcept C143998085 @default.
- W2154864146 hasConcept C168563851 @default.
- W2154864146 hasConcept C2776694085 @default.
- W2154864146 hasConcept C2776755627 @default.
- W2154864146 hasConcept C2777176818 @default.
- W2154864146 hasConcept C2780456651 @default.
- W2154864146 hasConcept C2780835546 @default.
- W2154864146 hasConcept C509974204 @default.
- W2154864146 hasConcept C530470458 @default.
- W2154864146 hasConcept C71924100 @default.
- W2154864146 hasConceptScore W2154864146C121608353 @default.
- W2154864146 hasConceptScore W2154864146C126322002 @default.
- W2154864146 hasConceptScore W2154864146C141071460 @default.
- W2154864146 hasConceptScore W2154864146C143998085 @default.
- W2154864146 hasConceptScore W2154864146C168563851 @default.
- W2154864146 hasConceptScore W2154864146C2776694085 @default.
- W2154864146 hasConceptScore W2154864146C2776755627 @default.
- W2154864146 hasConceptScore W2154864146C2777176818 @default.
- W2154864146 hasConceptScore W2154864146C2780456651 @default.
- W2154864146 hasConceptScore W2154864146C2780835546 @default.
- W2154864146 hasConceptScore W2154864146C509974204 @default.
- W2154864146 hasConceptScore W2154864146C530470458 @default.
- W2154864146 hasConceptScore W2154864146C71924100 @default.
- W2154864146 hasIssue "2" @default.